Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Galveston National Laboratory, University of Texas Medical Branch, Galveston.
J Infect Dis. 2018 Nov 22;218(suppl_5):S582-S587. doi: 10.1093/infdis/jiy293.
A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.
一种表达马尔堡病毒（MARV）穆索克变异株糖蛋白的重组水疱性口炎病毒（rVSV）完全保护猕猴免受 2 种 MARV 变异株和 Ravn 病毒的侵害，可作为预防性疫苗，也可用于 MARV 变异株穆索克的暴露后治疗。为了评估针对最具致病性的 MARV 变异株——安哥拉的暴露后疗效，我们构建了表达同源安哥拉糖蛋白的 rVSVs。用高剂量或低剂量的变异安哥拉对猕猴进行攻毒，并在暴露后 20-30 分钟进行治疗。高剂量和低剂量攻毒后，分别有 25%和 60%-75%的治疗猕猴存活。与穆索克变异株相比，安哥拉变异株的疾病进展更快，这可能是观察到的不完全保护的原因。
